Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the sale, the director directly owned 384,682 shares of the company’s stock, valued at $73,281,921. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $186.95 on Friday. The company’s 50 day simple moving average is $177.39 and its 200-day simple moving average is $162.16. The firm has a market cap of $11.51 billion, a PE ratio of -31.31, a price-to-earnings-growth ratio of 0.33 and a beta of 0.23. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $198.00. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, beating the consensus estimate of $6.49 by $0.15. The firm had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. Jazz Pharmaceuticals’s revenue for the quarter was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.51 EPS. As a group, equities analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Hilltop National Bank acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth approximately $36,000. LRI Investments LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $38,000. Farther Finance Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 754.8% in the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 234 shares in the last quarter. Leonteq Securities AG purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $50,000. Finally, GoalVest Advisory LLC acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth $51,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on JAZZ. Royal Bank Of Canada increased their target price on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Friday, March 27th. Needham & Company LLC increased their price objective on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Morgan Stanley lifted their target price on Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, Bank of America upped their price target on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $215.38.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.